Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | June 27, 2022 | June 30, 2022 |
| CTS CORPCTS · Entity 4654 | Director | November 06, 2025 | November 10, 2025 |
| ELI LILLY & CoLLY · Entity 2794 | SVP & President, Lilly Int'l | February 08, 2021 | February 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date June 27, 2022 · Filed June 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-06-27 | Direct | 115,919 |
Reported balance
After 2022-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-27 · Grant · Acquired 115,919 · Balance 115,919 F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 93,750 |
Reported balance
After 2022-06-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-27 · Grant · Acquired 93,750 · Balance 93,750 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.
F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year.
F5: Not applicable.
CTS CORP
Report date November 06, 2025 · Filed November 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,913 |
Reported balance
After 2025-11-06 transaction · row 1
1 source rowRow 1 · 2025-11-06 · Grant · Acquired 3,500 · Balance 35,913 F1: Restricted stock units vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest 100% on the first anniversary of the grant date, contingent upon the recipient's continued service as a director through the vesting date.
ELI LILLY & Co
Report date February 08, 2021 · Filed February 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,947 |
Reported balance
After 2021-02-08 transaction · row 1
1 source rowRow 1 · 2021-02-08 · Grant · Acquired 29,037 · Balance 56,947 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2022-02-01 | Direct | 10,706 |
Reported balance
After 2021-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-08 · Grant · Acquired 10,706 · Balance 10,706 F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,667 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,667 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Calidi Biotherapeutics, Inc.
Report date December 21, 2023 · Filed January 05, 2024
Section 16 reporting ended · disclosed 2024-01-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,301 |
Reported balance
After 2023-12-21 transaction · row 1
1 source rowRow 1 · 2023-12-21 · Grant · Acquired 5,644 · Balance 133,301 F1: Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023.
Syneos Health, Inc.
Report date September 28, 2023 · Filed September 28, 2023
Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-28 · Disposition to issuer · Disposed 3,493 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.
F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,
F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2018 Filed Oct 5, 2018 18:08 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 7,000 | $114.64 | $802,480.00 |
DisclosureSEC source: 0000059478-18-000240 · wf-form4_153876291479874.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,224 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $114.17 to $115.00. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 18, 2018 Filed Sep 19, 2018 21:47 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,000 | $107.00 | $321,000.00 |
DisclosureSEC source: 0000059478-18-000225 · wf-form4_153739365291067.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,224 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2018. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:47 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,000 | $105.61 | $316,830.00 |
DisclosureSEC source: 0000059478-18-000225 · wf-form4_153739365291067.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,224 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2018. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:33 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 15,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000074 · wf-form4_151787358167346.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,993 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:33 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 7,133 | $81.45 | $580,982.85 |
DisclosureSEC source: 0000059478-18-000074 · wf-form4_151787358167346.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,224 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:33 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 15,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000074 · wf-form4_151787358167346.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000056 · wf-form4_151744053419039.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,722 Underlying: Common Stock · 9,722 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 9,316 | $87.60 | $816,081.60 |
DisclosureSEC source: 0000059478-18-000056 · wf-form4_151744053419039.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,364 Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 22:35 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,532 | $86.00 | $303,752.00 |
DisclosureSEC source: 0000059478-17-000241 · wf-form4_151251332901839.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,048 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2017. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 17:55 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 2,003 | $83.67 | $167,591.01 |
DisclosureSEC source: 0000059478-17-000206 · wf-form4_151059570795341.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,580 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2017. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 15:02 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 15,000 | $77.66 | $1,164,900.00 |
DisclosureSEC source: 0000059478-17-000091 · wf-form4_148656613305978.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,583 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:20 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 6,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000084 · wf-form4_148615321334676.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,659 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:20 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 3,127 | $77.03 | $240,872.81 |
DisclosureSEC source: 0000059478-17-000084 · wf-form4_148615321334676.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,583 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:20 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 6,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000084 · wf-form4_148615321334676.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:34 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 15,993 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000055 · wf-form4_148590564225593.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,993 Underlying: Common Stock · 15,993 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:34 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 13,150 | $75.38 | $991,247.00 |
DisclosureSEC source: 0000059478-17-000055 · wf-form4_148590564225593.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,051 Read SEC document |
| December 16, 2016 Filed Jan 27, 2017 17:25 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000021 · wf-form5_148553794289692.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,901 Read SEC document |
| April 27, 2016 Filed Apr 28, 2016 19:43 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 12,000 | $76.27 | $915,240.00 |
DisclosureSEC source: 0000059478-16-000348 · wf-form4_146187262036158.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,101 F1 · price: This transaction was executed in multiple trades at prices ranging from $76.25 to $76.33. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2016 Filed Feb 2, 2016 20:32 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 5,000 | $78.75 | $393,750.00 |
DisclosureSEC source: 0000059478-16-000281 · wf-form4_145444515531055.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,101 Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:57 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 6,659 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000278 · wf-form4_145402543930711.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,659 Underlying: Common Stock · 6,659 shares Expires 2017-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 26, 2016 Filed Jan 28, 2016 23:57 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 7,035 | $81.96 | $576,588.60 |
DisclosureSEC source: 0000059478-16-000278 · wf-form4_145402543930711.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,101 Read SEC document |
| November 20, 2015 Filed Nov 23, 2015 20:45 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/06 (right to buy) · Derivative | 12,048 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0000059478-15-000197 · wf-form4_144831152291512.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,048 shares Expires 2016-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2015 Filed Nov 23, 2015 20:45 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 9,674 | $83.72 | $809,907.28 |
DisclosureSEC source: 0000059478-15-000197 · wf-form4_144831152291512.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,066 Read SEC document |
| November 20, 2015 Filed Nov 23, 2015 20:45 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 12,048 | $56.18 | $676,856.64 |
DisclosureSEC source: 0000059478-15-000197 · wf-form4_144831152291512.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:50 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11,532 | $70.97 | $818,426.04 |
DisclosureSEC source: 0000059478-15-000046 · wf-form4_142265822009833.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,692 Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 21,302 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000185 · wf-form4_141581383492359.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,302 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 19,254 | $66.96 | $1,289,247.84 |
DisclosureSEC source: 0000059478-14-000185 · wf-form4_141581383492359.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,160 Read SEC document |
| November 07, 2014 Filed Nov 12, 2014 17:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 21,302 | $55.65 | $1,185,456.30 |
DisclosureSEC source: 0000059478-14-000185 · wf-form4_141581383492359.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 15:17 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000159 · wf-form4_141234941394598.xml · derivative · entry 4 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,333 shares Expires 2014-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 15:17 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,384 | $64.85 | $284,302.40 |
DisclosureSEC source: 0000059478-14-000159 · wf-form4_141234941394598.xml · nonDerivative · entry 2 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,112 Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 15:17 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000159 · wf-form4_141234941394598.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2014 Filed Jan 31, 2014 01:33 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11,333 | $54.23 | $614,588.59 |
DisclosureSEC source: 0000059478-14-000040 · wf-form4_139113197450628.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP& Pres., Emerging Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,163 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.